256 related articles for article (PubMed ID: 15152479)
1. [AAV vector-mediated gene transfer and its application to the nervous system].
Ozawa K
Rinsho Shinkeigaku; 2003 Nov; 43(11):835-8. PubMed ID: 15152479
[TBL] [Abstract][Full Text] [Related]
2. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
3. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Sánchez-Pernaute R; Harvey-White J; Cunningham J; Bankiewicz KS
Mol Ther; 2001 Oct; 4(4):324-30. PubMed ID: 11592835
[TBL] [Abstract][Full Text] [Related]
4. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
5. [Gene therapy using AAV].
Ozawa K
Uirusu; 2007 Jun; 57(1):47-55. PubMed ID: 18040154
[TBL] [Abstract][Full Text] [Related]
6. Adeno-associated virus-mediated gene transfer of human aromatic L-amino acid decarboxylase protects mixed striatal primary cultures from L-DOPA toxicity.
Doroudchi MM; Liauw J; Heaton K; Zhen Z; Forsayeth JR
J Neurochem; 2005 May; 93(3):634-40. PubMed ID: 15836622
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for Parkinson's disease.
Lawlor PA; During MJ
Expert Rev Mol Med; 2004 Mar; 6(5):1-18. PubMed ID: 15000692
[TBL] [Abstract][Full Text] [Related]
8. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
Mandel RJ; Snyder RO; Leff SE
Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
[TBL] [Abstract][Full Text] [Related]
9. [Gene therapy and cell transplantation for Parkinson's disease].
Muramatsu S
Rinsho Shinkeigaku; 2005 Nov; 45(11):902-4. PubMed ID: 16447758
[TBL] [Abstract][Full Text] [Related]
10. [Gene therapy for Parkinson's disease: studies in animal models].
Muramatsu S
Rinsho Shinkeigaku; 2001 Dec; 41(12):1157-9. PubMed ID: 12235825
[TBL] [Abstract][Full Text] [Related]
11. HIV-2 derived lentiviral vectors: gene transfer in Parkinson's and Fabry disease models in vitro.
D'Costa J; Harvey-White J; Qasba P; Limaye A; Kaneski CR; Davis-Warren A; Brady RO; Bankiewicz KS; Major EO; Arya SK
J Med Virol; 2003 Oct; 71(2):173-82. PubMed ID: 12938190
[TBL] [Abstract][Full Text] [Related]
12. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector.
During MJ; Samulski RJ; Elsworth JD; Kaplitt MG; Leone P; Xiao X; Li J; Freese A; Taylor JR; Roth RH; Sladek JR; O'Malley KL; Redmond DE
Gene Ther; 1998 Jun; 5(6):820-7. PubMed ID: 9747462
[TBL] [Abstract][Full Text] [Related]
13. Adeno-associated virus vector-mediated triple gene transfer of dopamine synthetic enzymes.
Fan D; Shen Y; Kang D; Nakano I; Ozawa K
Chin Med J (Engl); 2001 Dec; 114(12):1276-9. PubMed ID: 11793852
[TBL] [Abstract][Full Text] [Related]
14. [Present status and future prospects for gene therapy in Parkinson's disease].
Muramatsu S
Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1461-6. PubMed ID: 13677895
[No Abstract] [Full Text] [Related]
15. Recombinant adeno-associated viral vectors bring gene therapy for Parkinson's disease closer to reality.
Muramatsu S; Wang L; Ikeguchi K; Fujimoto K; Nakano I; Ozawa K
J Neurol; 2002 Sep; 249 Suppl 2():II36-40. PubMed ID: 12375062
[TBL] [Abstract][Full Text] [Related]
16. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model.
Yang X; Mertens B; Lehtonen E; Vercammen L; Bockstael O; Chtarto A; Levivier M; Brotchi J; Michotte Y; Baekelandt V; Sarre S; Tenenbaum L
J Gene Med; 2009 Oct; 11(10):899-912. PubMed ID: 19639608
[TBL] [Abstract][Full Text] [Related]
17. [Gene therapy for Parkinson's disease].
Muramatsu S
Brain Nerve; 2007 Apr; 59(4):425-30. PubMed ID: 17447529
[TBL] [Abstract][Full Text] [Related]
18. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
Sajadi A; Bauer M; Thöny B; Aebischer P
J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
[TBL] [Abstract][Full Text] [Related]
19. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.
Kordower JH
Ann Neurol; 2003; 53 Suppl 3():S120-32; discussion S132-4. PubMed ID: 12666104
[TBL] [Abstract][Full Text] [Related]
20. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
